EcoDrugPlus

Neuronal Acetylcholine Receptor Subunit Alpha-2

Ensembl ID : ENSAMXG00000018597
Gene Symbol: LOC103025036
3 Cross references
195 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSAMXG00000038944
Gene Symbol: LOC103030483
3 Cross references
208 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSAMXG00000030647
Gene Symbol: LOC103033738
2 Cross references
186 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSAMXG00000006814
Gene Symbol: NPY2R
1 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSAMXG00000034879
Gene Symbol: LOC103047056
3 Cross references
178 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSAMXG00000012999
Gene Symbol: NTSR1
3 Cross references
133 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSAMXG00000003510
Gene Symbol: NTSR1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSAMXG00000011319
Gene Symbol: NTRK2
3 Cross references
210 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSAMXG00000039792
Gene Symbol: NTRK3
3 Cross references
198 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSAMXG00000012174
Gene Symbol: NTRK3
2 Cross references
178 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSAMXG00000024617
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSAMXG00000039006
Gene Symbol: NTRK3A
1 Cross references
157 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).